SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community members discuss its potential connection to Panasonic's recently announced solid-state battery development and the implications for Tesla, fueled by existing partnerships and shared board members. Investors are speculating on a potential partnership announcement given recent milestones, insider activity, and the broader shift towards solid-state battery technology. The community is closely watching for news that could drive the stock higher, with some drawing comparisons to past surges.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

Brera Holdings PLC ($BREA) is trending as traders discuss its shift to a Solana-based digital asset treasury named Solmate, fueled by a substantial $300 million private investment. The community is focused on the potential for significant gains, drawing comparisons to other crypto-related stocks that have experienced massive surges. Bullish sentiment is countered by some concerns about potential dilution and the sustainability of the pump.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as it approaches all-time highs, fueled by bullish sentiment around potential interest rate cuts and possible inclusion in the S&P 500. The community is actively discussing the stock's breakout potential, while also weighing the possibility of profit-taking after a significant run-up. Optimistic investors are highlighting long-term growth prospects and management's strategic vision, while short-term traders eye potential volatility around upcoming announcements.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending as the stock continues to decline despite having beat earnings and maintained guidance, leading to frustration and speculation of market manipulation among investors. Community members are debating whether to buy the dip, hold long-term, or cut losses, with some pointing to potential catalysts like future election ad revenue or a possible acquisition. Concerns about competition from walled gardens like Amazon and a recent analyst downgrade are also contributing to the negative sentiment.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx ($FDX) is trending following an earnings beat, though community sentiment is mixed due to a weaker-than-expected outlook and caution around tariffs. Discussions revolve around whether cost-cutting can offset potential headwinds and if the post-earnings dip presents a buying opportunity or signals deeper concerns. Traders are also watching the stock in relation to competitors like UPS and Amazon.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses its partnerships and real-world applications within the payroll and payment sectors. Recent focus is on their progress with regulatory compliance and anticipation for potential exchange listings. Community members are actively discussing staking and long-term potential, drawing comparisons to other established crypto projects.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the impact of recently ended tariff exemptions and potential for a dividend cut, despite a high current yield. Some traders are noting technical indicators suggesting a possible bottom, while others point to insider buying as a positive sign. Overall, community sentiment appears mixed as traders assess whether the current price reflects underlying economic concerns or presents a value opportunity.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar Corp. is trending following its Q3 earnings report, which revealed that the company missed expectations amidst ongoing housing market pressures. Community discussions are focused on the lowered guidance and potential impact of interest rates and inflation on the housing market, while some suggest that this may be a buying opportunity. The news is impacting the broader homebuilder sector, with attention on how Lennar's results reflect the overall health of the housing market.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending amid discussions around the cancellation of Jimmy Kimmel's show, sparking debates about free speech and cancel culture from both conservative and liberal viewpoints. The community is divided, with some calling for boycotts and others defending Disney's decision, creating volatility in the stock. Broader concerns include the company's handling of streaming services and its response to political pressures.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending following positive three-year data from its Phase 1 trial of Lonvo-z for hereditary angioedema, showing a significant reduction in attack rates. The community is discussing the potential for this to be a one-time treatment and is speculating about a short squeeze due to high short interest and potential acquisition interest from larger pharmaceutical companies.  Some traders are also citing positive technical indicators and potential sector rotation into biotech.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood Loves This Under-the-Radar AI Stock. Is It Time for You to Buy Now?

The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.

Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TEM_sentiment_and_message_volume_Feb_11_564e2ba31d.png" alt="TEM sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TEM sentiment and message volume Feb 11 as of 11:45 am ET | source: Stocktwits</figcaption></figure>CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.&nbsp;Another pointed to a bullish technical setup, predicting a move toward $80.<stembedurl>https://stocktwits.com/phijammaslamma/message/603757859</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/603746559</stembedurl>Tempus AI has gained a lot of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tem-stock-heads-for-best-rally-in-5-months/chb9WlYR8z">attention</a> since launching an AI-enabled personal health app last month.But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.&nbsp;TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.The research firm, however, thinks Ambry’s slower growth is a concern.Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.&nbsp;Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales 

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

Equity

Cathie Wood Just Doubled Down on This AI Stock. Should You?

The stock is one of the renowned investor’s top holdings.

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11.&nbsp;The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment, with conversations on Stocktwits turning more skeptical.Morgan Stanley cited a “more measured launch” for nexiguran ziclumeran, Intellia’s lead therapy for transthyretin amyloidosis, a rare and progressive heart disorder.&nbsp;The brokerage also pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.The analyst noted growing competition from non-gene-editing therapies, which could challenge Intellia’s position as a leader in “in vivo” CRISPR editing.&nbsp;Intellia’s approach reportedly delivers CRISPR components directly into the body to modify DNA, bypassing the need to engineer treatments from a patient’s cells.Earlier this month, Intellia announced a 27% workforce reduction and plans to halt&nbsp;the development of NTLA-3001 and some early-stage research programs.The company expects to incur $8 million in restructuring charges in the first quarter but believes the changes, combined with its cash balance of $862 million at the end of the fourth quarter, will extend its cash runway into the first half of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NTLA_sentiment_and_message_volume_Jan_27_414be9f90a.png" alt="NTLA sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>NTLA sentiment and message volume Jan 27 as of 11:40 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bearish’ following the downgrade.&nbsp;<stembedurl>https://stocktwits.com/KimAntony/message/601612137</stembedurl><stembedurl>https://stocktwits.com/CharlesEscobar/message/601578564</stembedurl><a href="https://stocktwits.com/symbol/NTLA">Intellia’s stock</a> has a high short interest of 21.3% and has lost nearly 60% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Options Alert: Should Investors Jump on This Cathie Wood-Owned Life Sciences Specialist?

While proteomics firms Quantum-Si has made waves recently, QSI stock might not be the long-term play value investors are seeking.

Intellia Therapeutics, Inc. ($NTLA) shares plunged hard on Thursday after the small-cap, clinical-stage biotech reported results from mid-stage study results of its CRISPR-based gene-editing therapy codenamed NTLA-2002 in patients with hereditary angioedema (HAE).HAE is a rare genetic disorder that manifests as severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body. The condition could lead to potentially life-threatening swelling attacks.&nbsp;The disorder has no curative therapies but current preventive therapies have to be administered lifelong.&nbsp;Intellia said the results from the Phase 2 study showed NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion.&nbsp;Among the findings from the study are:<ul><li>Both dose levels tested (25 mg and 50 mg) reduced mean monthly attacks, with the latter dose resulting in a 77% reduction during weeks 1-16 and 81% reduction in weeks 5-16.</li><li>Eight of the 11 patients in the 50 mg arm were completely attack free following one-time infusion</li><li>Safety and tolerability profiles were encouraging.</li></ul>“We are highly encouraged by these results, which we believe sets NTLA-2002 apart from other prophylaxis treatments. What was previously an unimaginable potential to be free of chronic therapy is one step closer to becoming a reality for the HAE community,” said John Leonard, CEO of Intellia.The company said it has selected the 50 mg formulation for evaluation in the global Phase 3 study dubbed ‘HALEO.’ Screening for the study is currently ongoing, it said.HAE therapeutics market was at $4.1 billion in 2023 and is estimated to grow at 9.2% compounded annual growth rate between 2024 and 2032,<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gminsights.com/industry-analysis/hereditary-angioedema-therapeutics-market"> according</a> to Global Market Insights.The negative reaction could be due to the “buy-the-rumor, sell-the-news” phenomenon as the stock tacked on about 17%&nbsp;gains from a near-term (Oct. 10) low of $17.09.<figure class="image"><a href="https://stocktwits.com/symbol/NTLA"><img style="aspect-ratio:633/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/intellia_sentiment_b2935066a6.png" alt="intellia-sentiment.png" width="633" height="142"></a><figcaption>NTLA sentiment and message volume October 24, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail trader sentiment was ‘extremely bearish’ (21/100), reversing from ‘bullish’ mood a day ago, with message volume spiking to ‘extremely high.’At 11:05 am ET, the stock was down 19.51% at $16.05, although off the day’s low of $15.52, which marked the lowest level in over four years.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ups-earnings-and-revenue-beat-estimates/cJ218XiR7Q">UPS Stock Soars Pre-Market, Keeps Retail Bullish As Q3 Beat Pleases Wall Street</a>For updates and corrections email newsroom@stocktwits.com

Intellia's mid-stage gene-editing therapy study results did not impress investors.

Intellia Stock Plunges To 4-Year Low Despite Promising Mid-Stage Study Results For Rare Genetic Disorder Therapy, Retail Sentiment Dips

Intellia stock tumbled to its lowest level in over four years as investors shrugged off what the company touted as promising results for its hereditary angioedema investigational gene-editing therapy.

Shares of Moderna plunged nearly 17% during the pre-market session after the company trimmed its full-year forecast. It cited low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion from its respiratory franchise compared to previous guidance of $4 billion.Following the announcement, retail sentiment dipped into ‘extremely bearish’ territory (16/100) souring further from yesterday’s ‘bearish’ reading.<figure class="image"><a href="https://stocktwits.com/symbol/MRNA"><img style="aspect-ratio:786/224;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_33_23_AM_44abb6c210.png" alt="Moderna sentiment meter as of 8:47 a.m. on August 01, 2024" width="786" height="224"></a><figcaption>Moderna sentiment meter as of 8:47 a.m. on August 01, 2024</figcaption></figure>On a positive note, the vaccine-maker reported an earnings loss of $3.33 during the second quarter versus an estimated loss of $3.39. Revenue came in at $241 million compared to a forecast of $132 million. Despite beating the analyst estimate, revenue declined 30% year-over-year (YoY) weighed down by decreased sales of the company's COVID-19 vaccine.Stéphane Bancel, Chief Executive Officer of Moderna stated that the firm has significantly lowered its operating costs during the second quarter. “We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.,” he said.Bancel stated the firm is involved in discussions with governments across Europe but some of them have pointed toward a tight budget restraining their capacity to buy more vaccines. The firm reportedly expects to see sales growth by 2025 and hit a breakeven position by 2026.Retail investors aren’t happy with the full-year guidance trim and the company’s efforts on the Covid vaccine given that its demand remains uncertain. One Stocktwits user expressed his ‘bearish’ view by stating that Moderna lowered its already lowered guidance, a sign it still has work to do in sufficiently diversifying its revenue streams.<figure class="image"><a href="https://stocktwits.com/JonOliNYC2020/message/581403885"><img style="aspect-ratio:794/160;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_34_35_AM_028dd1393e.png" alt="Stocktwits user JonOliNYC2020's post on Moderna stock " width="794" height="160"></a><figcaption>Stocktwits user JonOliNYC2020's post on Moderna stock&nbsp;</figcaption></figure>

Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion

Moderna Surpassed Q2 Earnings Estimates: Here’s Why Retail Sentiment Is ‘Extremely Bearish’ And The Stock Is Down 17%

While the vaccine-maker’s revenues beat estimates and its loss narrowed, management slashed its full-year sales forecast. Moreover, its struggles with EU sales and uncertainty over COVID vaccine demand remain key concerns for investors.

ARK Investment Management LLC - ARK Genomic Revolution ETF

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARKG News

ARKG ARK Investment Management LLC - ARK Genomic Revolution ETF